Drug Trial Radar · NCT02622321
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants With Inhibitors
Last checked: Nov 19, 2026Latest source record: Jun 24, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
113
Actual
Start
Nov 18, 2015
Primary completion
Oct 25, 2016
Study completion Dec 1, 2020
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- Collaborators
- Chugai Pharmaceutical
- First posted
- Dec 4, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This multicenter, open-label study will evaluate the safety, efficacy and pharmacokinetics of prophylactic emicizumab treatment in participants previously treated with episodic or prophylactic bypassing agents. Episodic bypassing agent participants will be randomized in a 2:1 fashion to receive emicizumab prophylaxis (Arm A) versus no prophylaxis (Arm B) and will be stratified across Arms A and B according to the number of bleeds they experienced over the last 24 weeks prior to study entry (less than \[\<\] 9 or greater than or equal to \[\>/=\] 9 bleeds); Arm B participants will have the opportunity to switch to emicizumab prophylaxis after at least 24 weeks on-study. Prophylactic bypassing agent participants will switch to emicizumab prophylaxis (Arm C) from the start of the trial; enrollment will be extended for 24 weeks after the last participant has enrolled in Arms A or B or until approximately 50 participants have enrolled in Arm C, whichever occurs first. Episodic bypassing agent participants who previously participated in the non-interventional study BH29768 (NCT02476942) who were unable to enroll in Arms A or B, or participants on prophylactic bypassing agents who were unable to enroll in Arm C, prior to their closure will have the opportunity to enroll in Arm D. Like participants in Arms A and C, Arm D participants will receive emicizumab prophylaxis from the start of the trial. All participants will continue to receive episodic bypassing agent therapy to treat breakthrough bleeds, preferably with recombinant activated factor VII (rFVIIa).
Conditions
- Hemophilia A
Interventions
EmicizumabDrug
Emicizumab will be administered at a loading dose of 3 milligrams per kilogram per week (mg/kg/week) subcutaneously (SC) for the first 4 weeks followed by a maintenance dose of 1.5 mg/kg/week SC up to the end of study. After at least 24 weeks on prophylactic emicizumab, individuals who experience suboptimal bleeding control on emicizumab (according to protocol-defined criteria) will have the opportunity to increase their dose to 3 mg/kg weekly.
rFVIIaDrug
Participants will continue to receive rFVIIa.
aPCCDrug
Participants will continue to receive aPCC.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Model-Based Annualized Bleed Rate (ABR) for Treated Bleeds, Arm A: Emicizumab Versus Arm B: No ProphylaxisTime frame: From Baseline up to 24 weeks (median [min-max] efficacy observation periods in Arm A vs. Arm B: 29.29 [0.1-48.9] weeks vs. 24.14 [23.0-26.0] weeks)
Locations
44 sites in 14 countries. Site status is shown where the registry gives one.
Children's Hospital Los Angeles
Los Angeles, California
Santa Monica Oncology Center
Santa Monica, California
University of Colorado Denver, Children's Hospital
Aurora, Colorado
Winship Cancer Institute
Atlanta, Georgia
Boston Childrens Hospital
Boston, Massachusetts
Children's Hospital of Michigan; Pediatrics
Detroit, Michigan
Cornell Univ Medical College; Hematology-Oncolog
New York, New York
Oregon Health & Science Uni ; Dept of Pediatrics
Portland, Oregon
Pennsylvania State Hershey Medical Center; Division of Hematology/Oncology, H046
Hershey, Pennsylvania
Univ of TX Health Science Ctr; Gulf States Hemo and Throm Ctr
Houston, Texas
Bloodworks Northwest (formerly Puget Sound Blood Center); Hemophilia
Seattle, Washington
Royal Prince Alfred Hospital; Haematology
Camperdown, New South Wales, Australia
The Alfred Hospital, Melbourne; Thrombosis and Haemostasis Unit
Melbourne, Victoria, Australia
ICIC
San José, Costa Rica
Hopital Cardio-vasculaire Louis Pradel; Hemostase clinique
Bron, France
CH de Bicetre; Centre de Traitement d' Hemophilie
Le Kremlin-Bicêtre, France
Hopital Cardiologique; Hematologie B
Lille, France
Groupe Hospitalier Necker Enfants Malades
Paris, France
Universitätsklinikum Bonn; Institut für Experimentelle Hämatologie und Transfusionsmedizin
Bonn, Germany
CTC North GmbH & Co. KG am Universitätsklinikum Hamburg-Eppendorf
Hamburg, Germany
Hämophilie-Zentrum Rhein Main GmbH
Mörfelden-Walldorf, Germany
IRCCS Ca' Granda Ospedale Maggiore Policlinico; Centro Emofilia e Trombosi "Angelo Bianchi e Bonomi"
Milan, Lombardy, Italy
AOU Careggi; SOD Malattie Emorragiche
Florence, Tuscany, Italy
Nagoya University Hospital
Aichi, Japan
Hiroshima University Hospital
Hiroshima, Japan
Hyogo College of Medicine Hospital
Hyōgo, Japan
St. Marianna University School of Medicine Hospital
Kanagawa, Japan
Hospital of the University of Occupational and Environmental Health,Japan
Kitakyushu-shi, Japan
Nara Medical University Hospital
Nara, Japan
Tokyo Medical University Hospital
Tokyo, Japan
Auckland City Hospital; Auckland Haemophilia Centre
Auckland, New Zealand
Uniwersyteckie Centrum Kliniczne; Klinika Hematologii i Transplantologii
Gdansk, Poland
SPSK Nr1 Klinika Hematoo&Transpl.Szpiku
Lublin, Poland
ALVAMED Lekarskie Gabinety Specjalistyczne
Poznan, Poland
Instytut Hematologii i Transfuzjologii; Klinika Zaburzeń Hemostazy i Chorób Wewnętrznych
Warsaw, Poland
Charlotte Maxeke Johannesburg Hospital; Haemophilia Comprehensive Care Center
Johannesburg, South Africa
Severance Hospital
Seoul, South Korea
Hospital Universitario la Paz; Servicio de Hematologia
Madrid, Spain
Hospital Universitario Virgen del Rocio; Servicio de Hematologia
Seville, Spain
Hospital Universitario la Fe; Servicio de Hematologia
Valencia, Spain
Showing 40 of 44 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.